Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

By S. Black. Jornal de Pediatria, 2003

1,085 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e3f08208acfda6f158d6d25982f543531d005649

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Brouwer
2. L. Mandell
3. D. van de Beek
4. T. Pilishvili
5. A. Tunkel
6. R. Wunderink
7. A. Anzueto
8. J. Bartlett

Citations in the corpus

• Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. (2005, background): “Consistent with PCV-7’s ability to interrupt transmission, declines in invasive pneumococcal disease incidence among older adults were observed in 2001, the year after PCV-7 introduction.(5) Our purpose was to closely examine disease in older adults in the conjugate vaccine era.”
• Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (2007, background): “The pneumococcal conjugate vaccine is under investigation for use in adults but is currently only licensed for use in young children [314, 315].”
• Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis (2010, background): “In a study of population-based data from the Active Bacterial Core Surveillance from the CDC after licensure of the heptavalent pneumococcal conjugate vaccine, there was a 59% decline in the rates of pneumococcal meningitis in children younger than 2 years of age (348).”
• Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. (2007, background): “Through 2003 the adjusted overall decline in IPD in Alaska Native children younger than 2 years (67%) was similar to that reported elsewhere in the United States (69%).(7) However, a more than doubling of non-PCV7 serotype disease between 2001-2003 and 2004-2006 eroded the overall decline to 41%.”
• Guidelines for the management of adult lower respiratory tract infections - Full version (2011, unknown): “Since the start of vaccination of children with PCV in the USA in 2000 a marked reduction of IPD has been noted both in the vaccinated cohorts and in adults [534,535].”
• Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. (2010, methodology): “We identified IPD cases through Active Bacterial Core surveillance (ABCs), an active population- and laboratory-based system [5, 12].”
• Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. (2007, background): “In 2000, the 7-valent protein-polysaccharide conjugate vaccine (PCV7 [Prevnar]; Wyeth Lederle Vaccines) was licensed for use in infants and young children in the United States and led to a dramatic decrease in the rate of invasive pneumococcal disease [1, 2].”